Isabella Ciccone, MPH

Carol Rosen, MD, professor emerita of pediatrics at Case Western Reserve University School of Medicine, discussed the transformation of pediatric sleep medicine from a clinical curiosity to a core medical specialty at SLEEP 2026.

AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.

At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells in MS. [WATCH TIME: 6 minutes]

TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.

At CMSC 2026, the director of the multiple sclerosis research unit at Ottawa Hospital discussed how integrating clinical research into MS practice enhances clinician expertise. [WATCH TIME: 5 minutes]

Findings from a 25-year analysis showed that tiapride was associated with significantly fewer adverse effect–related discontinuations than tetrabenazine in patients with Huntington disease chorea.

A sleep specialist and sleep patient advocate discussed diagnostic and patient-reported outcome measures that aim to better capture the cognitive, functional, and psychosocial burden of central disorders of hypersomnolence.

Optometrist DeAnn Fitzgerald, OD, discussed strategies to identify vision-related symptoms of TBI, the role of detailed history-taking, and the cultural considerations when caring for Hispanic patients.

Catch up on any of the neurology headlines you may have missed in June 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

Results from the Baby-COMET study of avalglucosidase alfa in infantile-onset Pompe disease will support a planned US regulatory submission for a label extension, anticipated in the second half of 2026.

New findings suggest that monoclonal antibody therapy was associated with a 34% lower risk of relapse in patients with AQP4-IgG seropositive NMOSD compared with those who were seronegative.

The professor of neurology at Wake Forest School of Medicine discussed the evolution of sleep medicine education, its relevance across neurologic specialties, and advice for early-career clinicians.

The FDA accepted supplemental applications seek to convert the accelerated approvals of casimersen and golodirsen to traditional approvals in patients with Duchenne muscular dystrophy.

Additional analyses from a phase 2 study evaluating the effects of zervimesine on hallucination in DLB will be presented at the Alzheimer's Association International Conference 2026 .

The FDA will review Capricor Therapeutics' Deramiocel for the treatment of Duchenne muscular dystrophy on July 29, 2026, ahead of the therapy's PDUFA target action date of August 22, 2026.

The ongoing phase 3 RELIEVE trial investigates the efficacy and safety of remibrutinib in patients with generalized myasthenia gravis who are on stable standard-of-care treatment.

A $2.5 million Michael J. Fox Foundation grant is funding 4 new sites for the NEULARK trial assessing NEU-411 as a potential disease-modifying therapy in genetically selected patients with early Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

A recently published 20-year study suggests that preoperative putamen volume on MRI independently can predict motor response to GPi-DBS in patients with dystonia-dyskinesia syndrome secondary to perinatal hypoxic-ischemic encephalopathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD Trial Navigator program helps to identify individuals with Parkinson Disease who may be eligible for the phase 2 NEULARK study. [WATCH TIME: 4 minutes]

The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]

A pair of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

Bevacizumab becomes approved in Japan for neurofibromatosis type 2 following phase 2 data that suggested potential effects on hearing preservation and tumor volume despite the study not meeting its primary efficacy end point.

The associate clinical professor at the University of South Carolina School of Medicine discussed data presented at SLEEP 2026 from a phase 2 study of orexin 2 receptor agonist alixorexton in narcolepsy type 2. [WATCH TIME: 3 minutes]

The FDA has accepted Regeneron Pharmaceuticals’ new drug application of cemdisiran's for generalized myasthenia gravis under priority review, with a target action date of November 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.